NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Search Results for CEL-SCI Corporation


Filter Articles: Clinical News | Consumer News | Business News | All News | More Options

Results 1 - 20      Next >


 Refine Search
Display Mode: Context | Summary
CEL SCI Collaborators Demonstrate Novel L.E.A.P.S. Vaccines Immunize Mice Against Tuberculosis Antigens and Suggest Potential to Treat Swine and Other Influenzas
2009 JUN 15 ... CEL-SCI Corporation (NYSE AMEX: CVM) announced that its collaborators at the University of Hawaii reported ...
Subject: Tuberculosis
Price: $3.00
*
CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response
2009 NOV 23 ... CEL-SCI Corporation (NYSE Amex: CVM) announced that Dr. Kenneth S. Rosenthal, Professor of Immunology and ...
Subject: Herpes Simplex
Price: $3.00
*
CEL-SCI Completes $5.85 Million Registered Direct Offering
2009 JUL 13 ... CEL-SCI Corporation (NYSE Amex: CVM), a late stage cancer immunotherapy company, announced that it has ...
Subject: Cancer Vaccines
Price: $3.00
*
CEL-SCI Corporation Announces Elimination of $8.3 Million Convertible Notes
2009 SEP 14 ... CEL-SCI Corporation (NYSE AMEX: CVM), a developer of vaccines for the prevention and treatment of infectious ...
Subject: CEL-SCI Corporation
Price: $3.00
*
CEL-SCI Corporation Strengthens Balance Sheet Through Receipt of $10 Million From Warrant Exercises
2009 NOV 9 ... CEL-SCI Corporation (NYSE Amex: CVM) announced that it has received over $10 million over the past 60 days ...
Subject: CEL-SCI Corporation
Price: $3.00
*
CEL-SCI Corporation to Raise $20 Million in Registered Direct Offering
2009 SEP 28 ... Investors will also receive warrants to purchase 4,714,284 shares of CEL-SCI Corporation's common stock. The warrants have an exercise price of $1.50 per share and are ...
Subject: CEL-SCI Corporation
Price: $3.00
*
CEL-SCI Expands H1N1 Flu Virus Work
2009 AUG 31 ... CEL-SCI Corporation (NYSE Amex: CVM), announces that it is expanding the scope of its work towards creating ...
Subject: Vaccines
Price: $3.00
*
CEL-SCI Expands Testing of Its Vaccine to Determine Efficacy Against More Virulent Strain of H1N1 Swine and Other Influenza Viruses
2009 JUN 22 ... CEL-SCI Corporation (NYSE Amex: CVM) announced that it is expanding the pre-clinical testing of its flu ...
Subject: Vaccine Safety
Price: $3.00
*
CEL-SCI Files Patent Application to Support Company's Treatment for More Virulent Strain of H1N1 Swine and Other Influenza Viruses
2009 JUL 6 ... CEL-SCI CORPORATION (NYSE AMEX: CVM) announced that it has filed a provisional U.S. patent application ...
Subject: Bird Flu
Price: $3.00
*
CEL-SCI Hires Clinical Research Organization for Clinical Study With Hospitalized H1N1-Infected Patients
2009 OCT 5 ... CEL-SCI Corporation (NYSE AMEX: CVM), a developer of vaccines and therapeutics for the treatment of ...
Subject: Clinical Trial Research
Price: $3.00
*
CEL-SCI Posts New Corporate Presentation to Website
2009 JUL 6 ... CEL-SCI Corporation (NYSE Amex: CVM) announced that a new corporate presentation is available for review on ...
Subject: CEL-SCI Corporation
Price: $3.00
*
CEL-SCI Presents Data at American College of Rheumatology Conference Which Suggests that CEL-2000 Has Potential to Slow Damage Caused by Rheumatoid Arthritis
2009 NOV 2 ... CEL-SCI Corporation (NYSE Amex: CVM) announced the presentation of new rheumatoid arthritis data at the ...
Subject: Arthritis
Price: $3.00
*
CEL-SCI Presents Solid Science As Detractors Keep Changing the Subject
2009 OCT 19 ... to a community of highly informed investors, has issued a special editorial report about CEL-SCI Corporation's (NYSE AMEX:CVM) presentation of data about the company's dendritic H1N1 treatment, ...
Subject: BioMedReports.com
Price: $3.00
*
CEL-SCI Scientist Invited to Discuss Plans to Launch Unique Manufacturing Process That Saves Cost While Enhancing the Shelf Life of Drugs at 5th Annual Aseptic Processing of Sterile Drug Products Conference
2009 JUN 29 ... CEL-SCI Corporation (NYSE Amex: CVM) announced that Eyal Talor, Ph.D., Senior Vice President of Research and ...
Subject: CEL-SCI Corporation
Price: $3.00
*
CEL-SCI Signs Definitive Agreement to Raise $4.4 Million in Registered Direct Offering
2009 AUG 31 ... CEL-SCI Corporation. (NYSE Amex: CVM), a biotechnology company entering a late stage oncology trial and ...
Subject: CEL-SCI Corporation
Price: $3.00
*
CEL-SCI Signs Definitive Agreement to Raise $5 Million in Registered Direct Offering
2009 JUL 6 ... CEL-SCI Corporation (NYSE AMEX: CVM), a late stage cancer immunotherapy company, announced that it has ...
Subject: Cancer Vaccines
Price: $3.00
*
CEL-SCI to Commence First Clinical Study with Hospitalized H1N1 Infected Patients
2009 SEP 28 ... CEL-SCI Corporation (NYSE Amex: CVM), a developer of vaccines and therapeutics for the prevention and ...
Subject: Pandemics
Price: $3.00
*
CEL-SCI to Conduct First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients at Johns Hopkins University School of Medicine
2009 NOV 16 ... CEL-SCI Corporation (NYSE Amex: CVM), a developer of vaccines and therapeutics for the prevention and ...
Subject: Infectious Diseases
Price: $3.00
*
CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health NIH, National Cancer Institute NCI Seminar Series
2009 JUL 20 ... CEL-SCI Corporation (NYSE Amex: CVM), a late stage cancer immunotherapy company, announced that Dr. Eyal ...
Subject: CEL-SCI Corporation
Price: $3.00
*
Completion of Cel-Sci's New Facility Signals That Long Awaited Phase III Trial is Imminent
2009 NOV 9 ... intelligence to a community of highly informed investors, was given an exclusive tour of CEL-SCI Corporation's, (NYSE AMEX:CVM) new, state-of-the-art manufacturing facility near Baltimore, MD ...
Subject: BiomedReports.com
Price: $3.00
*

Results 1 - 20      Next >

-----------------------
Home | Free Newsletters | Products | Article Library | About Us | Contact | Privacy Policy | Search | Visit VerticalNews.com
Copyright © 2009 NewsRx		 PR Login